Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Telmisartan/hydrochlorothiazide-induced hepatotoxicity.

Lorena M, Autolitano A, Natale G, Uberti F, Vitali F, Schiantarelli C, Liberato NL.

Arch Med Sci. 2015 Aug 12;11(4):893-4. doi: 10.5114/aoms.2015.53311. Epub 2015 Aug 11. No abstract available.

2.

Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes.

Abdelsaid M, Coucha M, Ergul A.

Transl Res. 2014 Nov;164(5):424-32. doi: 10.1016/j.trsl.2014.06.003. Epub 2014 Jun 17.

3.

Modulation of lipid metabolic defects rescues cleft palate in Tgfbr2 mutant mice.

Iwata J, Suzuki A, Pelikan RC, Ho TV, Sanchez-Lara PA, Chai Y.

Hum Mol Genet. 2014 Jan 1;23(1):182-93. doi: 10.1093/hmg/ddt410. Epub 2013 Aug 23.

4.

The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle.

Lastra G, Santos FR, Hooshmand P, Hooshmand P, Mugerfeld I, Aroor AR, Demarco VG, Sowers JR, Henriksen EJ.

Cardiorenal Med. 2013 Jul;3(2):154-164. Epub 2013 Jun 25.

5.

Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.

Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E, Hirata Y, Kurobe H, Maeda N, Sakaue H, Masuzaki H, Shimomura I, Sata M.

Cardiovasc Diabetol. 2012 Nov 8;11:139. doi: 10.1186/1475-2840-11-139.

6.

Cardiac insulin resistance and microRNA modulators.

Pulakat L, Aroor AR, Gul R, Sowers JR.

Exp Diabetes Res. 2012;2012:654904. doi: 10.1155/2012/654904. Epub 2011 Jul 31. Review.

7.

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

Unger T, Paulis L, Sica DA.

Eur Heart J. 2011 Nov;32(22):2739-47. doi: 10.1093/eurheartj/ehr253. Epub 2011 Sep 27. Review.

8.

Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.

Pulakat L, DeMarco VG, Ardhanari S, Chockalingam A, Gul R, Whaley-Connell A, Sowers JR.

Am J Physiol Regul Integr Comp Physiol. 2011 Oct;301(4):R885-95. doi: 10.1152/ajpregu.00316.2011. Epub 2011 Aug 3. Review.

9.

New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Zhuo JL, Li XC.

Peptides. 2011 Jul;32(7):1551-65. doi: 10.1016/j.peptides.2011.05.012. Epub 2011 Jun 14. Review.

10.

Nitro-oleic acid inhibits angiotensin II-induced hypertension.

Zhang J, Villacorta L, Chang L, Fan Z, Hamblin M, Zhu T, Chen CS, Cole MP, Schopfer FJ, Deng CX, Garcia-Barrio MT, Feng YH, Freeman BA, Chen YE.

Circ Res. 2010 Aug 20;107(4):540-8. doi: 10.1161/CIRCRESAHA.110.218404. Epub 2010 Jun 17.

11.

Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities.

Dhaunsi GS, Yousif MH, Akhtar S, Chappell MC, Diz DI, Benter IF.

Eur J Pharmacol. 2010 Jul 25;638(1-3):108-14. doi: 10.1016/j.ejphar.2010.04.030. Epub 2010 May 4.

12.

Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy.

Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka C, Tanaka T, Fujikura J, Ebihara K, Hosoda K, Katsurada A, Ohashi N, Urushihara M, Kobori H, Morimoto N, Kawazoe T, Naitoh M, Okada M, Sakaue H, Suzuki S, Nakao K.

Am J Hypertens. 2010 Apr;23(4):425-31. doi: 10.1038/ajh.2009.263. Epub 2010 Jan 7.

Items per page

Supplemental Content

Write to the Help Desk